• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Brazil·Healthcare·PNVL3.SA
Share

Dimed S.A. Distribuidora de Medicamentos Stocks

R$ 12.46Last Updated 29.09.2026

Issuer Rating

6/7
Performance

Strong

Risk

Limited

Recommendation

Buy

Market Cap

R$ 350.24M

R$ 12.46
Key Takeaways

Risk factor

Modest price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Eldorado do Sul, Brazil, Dimed S.A. Distribuidora de Medicamentos is a Brazilian company that supplies a wide range of goods, including pharmaceuticals, fragrances, personal care products, cosmetics, and dermocosmetics. Its business model encompasses both retail and wholesale operations. The company distributes its merchandise through logistical hubs situated in the states of Rio Grande do Sul, Paraná, and Espírito Santo. Furthermore, it boasts an extensive retail network of 517 stores, located across Rio Grande do Sul, Santa Catarina, Paraná, and São Paulo. Before April 2000, the company was known as Panvel S.A. Drogarias e Farmacias.

Company Valuation

Undervalued
6/7

Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is underpriced on P/E, 'cheap' on EV/EBITDA, unde

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of PNVL3.SA is 17.8 and suggests 42.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.10.2026 07:30

The global government bond market experienced its worst quarter since 2024

01.10.2026 06:00

BMW will cut 20% of its management staff. The company is betting on AI

01.10.2026 03:27

Google has unveiled a new AI model. Will it help the company regain its lead in the AI race?

01.10.2026 02:07

A Record Year and a Strong Outlook: Did Micron's Report Confirm the Sustainability of the AI Boom?

01.10.2026 01:11

U.S. Regulator Investigates OpenAI and Anthropic Over AI Safety Concerns — SM

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026